Cladribine (CAS 4291-63-8) – Purine Analogue Antineoplastic API

Cladribine (CAS 4291-63-8) is a high-purity purine analogue antineoplastic API, featuring a stable nucleoside molecular structure designed to target rapidly dividing cells. It disrupts DNA synthesis by inhibiting ribonucleotide reductase and incorporating into cellular DNA, selectively inducing apoptosis in cancerous and overactive immune cells—with a favorable therapeutic index compared to broad-spectrum chemotherapies. This premium API exhibits excellent solubility and bioavailability, supporting consistent efficacy in injectable and oral formulations.

It caters to the core needs of oncology and immunology drug manufacturers, as well as clinical research institutions. Widely applied in developing treatments for hairy cell leukemia, chronic lymphocytic leukemia, and relapsing multiple sclerosis, it aligns with unmet clinical needs for targeted therapies. Produced under strict GMP standards, each batch undergoes rigorous purity testing to meet international pharmacopoeia requirements, ensuring safety and reliability for clinical use. For businesses prioritizing targeted, well-tolerated therapeutic solutions, this Cladribine API serves as a critical raw material for advancing oncology and immunology medication development.